Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Instil BioTIL -1.25%31 Net Margin % is 0.00% as of Mar. 2026. GuruFocus rates TIL with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Instil Bio ranks worse than 106269.82% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Instil Bio's Net Income for the
three
months ended in Mar. 2026 was $-4.20 Mil. Instil Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Instil Bio's net margin for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Instil Bio's Net Margin % or its related term are showing as below:
TIL's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.56 * Ranked among companies with meaningful Net Margin % only.
Instil Bio (NAS:TIL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Instil Bio Net Margin % Related Terms
Instil Bio Net Margin % Historical Data
* Premium members only.
The historical data trend for Instil Bio's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Instil Bio's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's Net Margin % distribution charts can be found below:
* The bar in red indicates where Instil Bio's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (TIL) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Instil Bio and its competitors. According to the industry distribution chart, Instil Bio ranks #999999 out of 941 companies in the Biotechnology industry.
Is Instil Bio's Net Margin % too high?
Instil Bio's current Net Margin % is 0.00%. Based on the distribution chart, Instil Bio ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Instil Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Instil Bio's Net Margin % compare to AURX and MCRB?
According to the Biotechnology industry distribution chart, Instil Bio ranks #999999 out of 941 companies for Net Margin %. This places Instil Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Instil Bio and its competitors. Instil Bio's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instil Bio stock overvalued right now?
Instil Bio (TIL) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Instil Bio's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Instil Bio (TIL), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
31GF Score
Get the complete analysis for TIL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TIL has been successfully added to your 
